Behind the Bell: CARGO Therapeutics

In this episode of Behind the Bell, CARGO Therapeutics CEO Gina Chapman shares how Nasdaq helped the company navigate going public and the advancements that are still to come.

Transcript:

If it sparks your heart and soul and your energy and you're willing to work really hard for it, then do that and build a great team around you.

The vision from the very beginning is to honestly get curative therapy to patients who have lymphomas, B-cell lymphomas, and these patients have very high unmet need.

They've basically relapsed or are refractory to other treatments, the foundation of cargo is addressing multiple mechanisms of resistance, so that these therapies can deliver better outcomes to patients’ longer lives.

We are in a potentially pivotal phase-two study advancing the first program of therapy into patients, and we're very proud of what we do.

The employees at cargo have worked so hard, executing to really get this therapy to patients and our company built.

I just have an immense amount of pride for what they've achieved.

We've emerged earlier this year from seed stage, to so quickly turn around and now be listed on Nasdaq with some of the most incredible companies in the world, and to be amongst such elite company, it's exciting.